Literature DB >> 22527347

Bile acid is important for gastrointestinal absorption of nilotinib.

Akihito Fujimi, Naoto Takahashi, Masatomo Miura, Yuji Kanisawa, Kaoru Ono, Kenichi Sawada.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527347     DOI: 10.1007/s00228-012-1282-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.

Authors:  Naoto Takahashi; Masatomo Miura; Takenori Niioka; Kenichi Sawada
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-07       Impact factor: 3.333

2.  Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.

Authors:  Richard A Larson; Ophelia Q P Yin; Andreas Hochhaus; Giuseppe Saglio; Richard E Clark; Hirohisa Nakamae; Neil J Gallagher; Eren Demirhan; Timothy P Hughes; Hagop M Kantarjian; Philipp D le Coutre
Journal:  Eur J Clin Pharmacol       Date:  2011-12-30       Impact factor: 2.953

3.  High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma.

Authors:  Masatomo Miura; Naoto Takahashi; Ken-ichi Sawada
Journal:  Biomed Chromatogr       Date:  2010-07       Impact factor: 1.902

Review 4.  Clinical pharmacokinetics of tyrosine kinase inhibitors.

Authors:  Nielka P van Erp; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Cancer Treat Rev       Date:  2009-09-05       Impact factor: 12.111

5.  Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

Authors:  C Tanaka; O Q P Yin; V Sethuraman; T Smith; X Wang; K Grouss; H Kantarjian; F Giles; O G Ottmann; L Galitz; H Schran
Journal:  Clin Pharmacol Ther       Date:  2009-11-18       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.